Bone loss disorders can be treated or prevented by administration of an agent which increases the levels of oxidant defences and/or at least one antioxidant in a subject. The agent can be an antioxidant. The agent may act directly to increase antioxidant levels and/or oxidant defences. Alternatively, the agent may act indirectly.
